Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial

Bottom line: Retatrutide delivered 28.7% mean weight loss at 68 weeks in TRIUMPH-4, establishing a new benchmark for pharmacological obesity treatment and suggesting triple receptor agonism may be the next frontier in metabolic peptide therapy.

Retatrutide (LY3437943) is a once-weekly injectable peptide that simultaneously activates three incretin and metabolic hormone receptors — glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This triple agonist mechanism differentiates it from dual agonists like tirzepatide (GIP/GLP-1) and single-target agents like semaglutide (GLP-1 only).

TRIUMPH-4 Trial Design

The TRIUMPH-4 study (NCT05882045) was a randomized, double-blind, placebo-controlled Phase 3 trial enrolling adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity. The study evaluated the two highest investigational doses of retatrutide administered once weekly over 68 weeks.

Key Findings

Results announced by Eli Lilly on December 11, 2025 showed:

• Mean weight loss of 28.7% at 68 weeks at the highest dose — equivalent to approximately 71 lbs (32 kg) in a participant weighing 248 lbs at baseline.¹
• This exceeds the weight loss achieved by tirzepatide (approximately 22.5% in SURMOUNT-1) and semaglutide 2.4 mg (approximately 15% in STEP 1).²
• The glucagon receptor component is hypothesized to drive additional energy expenditure beyond what GLP-1/GIP agonism achieves alone, contributing to the superior efficacy.

Safety Profile

The most common adverse events were gastrointestinal in nature — nausea, diarrhea, and vomiting — consistent with the GLP-1 receptor agonist class. Rates were manageable with dose escalation. Full safety data from the TRIUMPH program are expected in peer-reviewed publications through 2026.

Clinical Implication

For prescribers managing treatment-resistant obesity, retatrutide's 28.7% weight reduction suggests that triple receptor agonism can achieve surgical-level weight loss pharmacologically. Clinicians should monitor the TRIUMPH program's remaining readouts (including cardiovascular outcomes data) and anticipate a potential regulatory filing in late 2026–2027. This compound may redefine first-line pharmacotherapy thresholds for severe obesity.

---

¹ Eli Lilly and Company. Press Release: TRIUMPH-4 topline results. December 11, 2025.

² Jastreboff AM, et al. N Engl J Med. 2022;387(4):327–340.